Key Points
- Coastlands Capital purchased 50,000 Bolt Biotherapeutics shares at an average price of $6.38, spending $319,000. Its stake rose 12.12% to 462,416 shares.
- Bolt reported quarterly earnings per share of negative $4.57, missing the analyst estimate of negative $3.39; revenue was $0.01 million versus expectations of $0.50 million.
- Analysts have a consensus Hold rating and an average price target of $14.50; ratings span two Buys, one Hold, and one Sell.
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT - Get Free Report) major shareholder Coastlands Capital Lp purchased 50,000 shares of the company's stock in a transaction that occurred on Monday, November 9th. The stock was bought at an average cost of $6.38 per share, for a total transaction of $319,000.00. Following the purchase, the insider directly owned 462,416 shares in the company, valued at $2,950,214.08. This trade represents a 12.12% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Bolt Biotherapeutics Price Performance
Shares of NASDAQ BOLT opened at $6.30 on Wednesday. The firm has a market cap of $12.16 million, a PE ratio of -0.38 and a beta of 0.85. The firm has a fifty day moving average of $4.50 and a 200 day moving average of $4.53. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61. Bolt Biotherapeutics, Inc. has a one year low of $3.10 and a one year high of $7.78.
Bolt Biotherapeutics (NASDAQ:BOLT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing analysts' consensus estimates of ($3.39) by ($1.18). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million. Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%. As a group, research analysts predict that Bolt Biotherapeutics, Inc. will post -11.10 EPS for the current fiscal year.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Bolt Biotherapeutics in a research note on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $14.50.
Read Our Latest Analysis on BOLT
Institutional Trading of Bolt Biotherapeutics
A hedge fund recently bought a new position in Bolt Biotherapeutics stock. Nan Fung Group Holdings Ltd acquired a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 5,000 shares of the company's stock, valued at approximately $19,250. Bolt Biotherapeutics makes up about 0.0% of Nan Fung Group Holdings Ltd's investment portfolio, making the stock its 25th largest position. Nan Fung Group Holdings Ltd owned 0.26% of Bolt Biotherapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 86.70% of the company's stock.
Bolt Biotherapeutics Company Profile
(
Get Free Report)
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company's approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt's proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
